Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

Scotland says no to Daiichi Sankyo’s cholesterol drug Nilemd...

The Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, saying the evidence backing the drug isn’t strong enough

After NICE okay, Scots denied access to Vifor’s Veltassa

The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the blood (hyperkalaemia), even

How does HTA for orphan drugs differ across Europe?

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe.

Novartis' Kymriah okayed for funding in Scotland for lymphom...

Novartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness body recommended funding in an aggressive form of lymphoma

Scotland backs Pfizer’s Ibrance for breast cancer